BDTX BLACK DIAMOND THERAPEUTICS INC Product Launches 8-K Filing 2023 - Phase 1 Dose Escalation Clinical Trial Topline Results in Patients with Recurrent GBM Black Diamond Therapeutics announced topline results from Phase 1 clinical trial of BDTX-1535 in patients with recurrent GBM, showing positive efficacy and safety data.Get access to all SEC 8-K filings of the BLACK DIAMOND THERAPEUTICS INC